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Introduction
We live in a world where more and more ideas and experiences are 
becoming forms of property. Intellectual property laws have expanded 
throughout the globe, and a broad range of creations and realms of 
human experience have been cordoned off, with legal fences being put 
around the sharing of innovations and cultural practices. Yoga routines, 
genetically engineered mice, French gastronomy, and the cultural prac­
tices of Afro-Brazilians have all been subject to ownership claims under a 
new global regime of intellectual property protections. We are also seeing 
extensions of laws that protect more familiar forms of intellectual prop­
erty. Copyright laws now keep vast collections of film and literature out 
of the public realm, while new patent laws make it harder both to share 
medical knowledge and to produce generic versions of medicines. United 
States court decisions, multinational corporations, and the World Trade 
Organization (WTO) are major contributors to this new regime in which 
knowledge that was once considered part of the public domain has be­
come the property of individuals, corporations, and communities.1 At the
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same time, counterefforts such as the Access to Knowledge movement, 
Creative Commons licensing, and Doctors Without Borders’ Access to Es­
sential Medicines program struggle to keep artistic creations, medications, 
and scientific knowledge in the public realm.2
In this new property regime that spans the globe from Indonesia to 
Brazil to the United States, India has been the site of some of the most 
fraught battles over the ownership of pharmaceutical knowledge. A center 
of medical knowledge for centuries, India is home to several non-Western 
medical systems that are taught in colleges and practiced in hospitals, 
and the country provides many of the world’s Western, biomedical drugs 
through its growing pharmaceutical sector.
Over the last ten years, as I spoke to people in the United States about 
the research I had been doing on controversies over patents in India, some 
would make comments about Indian companies “stealing” products from 
US companies or “violating” patents by producing “copies” of medica­
tions that were patented elsewhere. What most people who knew a little 
about this controversy did not know was that nothing illegal was going 
on. Before the WTO implemented its global patent rules, each country 
created its own patent laws tailored to its own priorities and concerns. 
India’s pre-WTO patent law had a provision stating that, for medications, 
only the process for making the medication, but not the medical product 
itself, could be patented. Thus, different companies could make the same 
medicine if they could find a different way to manufacture the drug, and, 
until recently, Indian companies were free to create their own versions of 
drugs that were patented elsewhere, whether antidepressants, treatments 
for AIDS, medications for erectile dysfunction, or the various statins, such 
as Pfizer’s Lipitor, that have been making huge profits for multinational 
drug companies.
The Indian government included this special product patent exception 
back in 1970 because it wanted to avoid monopoly control of medicines. 
Medications, because they could save a life or cure a disease, were not like 
other kinds of inventions in the minds of Indian lawmakers. In the United 
States, on the other hand, medicines have long been protected by product 
patents, and laws have conformed more closely to the interests of phar­
maceutical corporations, allowing what some critics today consider to be 
frivolous patents on slight modifications of drugs, known as “me-too” 
drugs, that offer no increase in efficacy. Over the course of the 1990s and
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2000s, the WTO required member nations to change their laws and con­
form to a single, United States-style intellectual property regime. In other 
words, India had to make its patent laws more like those of the United 
States because of the W TO ’s mandate. The deadline India and other de­
veloping countries were given was 2005, and India met this requirement 
when it passed its 2005 Patents (Amendment) Act.
One employee of a multinational pharmaceutical corporation whom I 
spoke to about this topic displayed the usual disdain for Indian companies 
“stealing” other companies’ ideas. National autonomy did not matter. In­
dia’s earlier law with its product patent exception was simply wrong in 
the view of this employee. If an Indian company made the same drug this 
person’s company patented, it should be illegal, and the 2005 law made it 
so. It was only later that I learned that the company this person worked 
for was one of several that produced products based on knowledge from 
India’s ayurvedic medical system for which no royalties or other com­
pensation were ever paid. While corporations have become more vigilant 
about safeguarding what they feel to be their intellectual property, the In­
dian government has been shoring up protections for what it considers to 
be Indian proprietary knowledge, such as the pharmacopoeia of ayurvedic 
medicine. This book examines the new world of increased restrictions on 
the use of medical knowledge, and on the production of the drug products 
that derive from this knowledge, and asks what is gained and lost in this 
new system of control.
While the WTO mandate, known as the Trade Related Aspects of Intel­
lectual Property Agreement, or TRIPS, limited the sharing of Western phar­
maceutical knowledge and production by expanding patents, some were 
concerned that it would also enable what is known as “biopiracy,” which 
is the plundering of local or indigenous knowledge to create commercial 
products for multinational companies. Indigenous peoples and practitio­
ners of non-Western systems of medicine in India, Brazil, and elsewhere 
became concerned that multinational companies would come prospecting 
for their knowledge about medicinal plants. They would learn of, say, a 
tropical shrub that treats stomach disorders used by the Ka’apor people in 
the Amazon or a tuber that has anti-inflammatory properties well known 
to practitioners of ayurvedic medicine in India, and they would then iso­
late the active ingredient in the plant to create a new product for which 
they would acquire patent rights. These concerns were not far-fetched, as
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the first effective antipsychotic in Western psychiatry was derived, and 
patented, by isolating the active ingredient in Rauwolfia serpentina, a 
plant used in Ayurveda to treat mental disorders. And an important early 
anesthetic was derived from an extract, curare, used by indigenous people 
in South America and made into a medication by a US company. These in­
novations were developed by pharmaceutical laboratories that eventually 
became, respectively, part of Novartis and Bristol-Myers Squibb, and both 
of these companies have been recently involved in patent disputes in India, 
asserting property rights for their own innovations. More recently, US 
and European patents have been issued based on knowledge from India 
of the properties of turmeric and the neem tree.3 There are numerous 
other examples of treatments derived from local or indigenous knowledge 
around the world, from birth control pills to cancer treatments. In fact, 
the legal scholar Ikechi Mgbeoji, in his study of biopiracy, estimates that 
“over one-quarter of modern drugs prescribed all over the world are di­
rectly derived from plant life forms, and most of them are products o f . . . 
traditional knowledge of the uses of plants.”4 If Mgbeoji’s assessment is 
correct, the struggle between corporate and indigenous knowledge of the 
medicinal effects of plants could be quite extensive.
It was unclear, however, how the W TO ’s new provision on intellectual 
property would affect non-Western medical systems, since it was oriented 
toward protecting corporate products and individual inventors and did 
not seem to change any rules that pertain to indigenous knowledge.5 Still, 
many in India, Brazil, and elsewhere were wary of the potential exploita­
tion of local knowledge, and in light of these concerns, India implemented 
laws based on the Convention on Biological Diversity, which was signed 
at the 1992 Rio Earth Summit, to provide protection for and benefit-sharing 
of indigenous knowledge. The Indian government also established the 
Traditional Knowledge Digital Library (TKDL) to codify knowledge and 
practices it considers national property, from yoga to the arts to treat­
ments from Indian medical systems.
The most prized aspect of India’s local knowledge that the government 
is trying to protect is Ayurveda, a contemporary, institutionalized medical 
system that has ancient roots. Ayurvedic medicine has grown in popularity 
in the West, but it is not quite the “holistic,” “natural,” or “spiritual” heal­
ing system that many people in the West believe it to be. Those outside of 
South Asia tend to imagine Ayurveda as akin to other “alternative” healing
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systems. These views are often shaped by a New Age outlook that sees 
all non-Western medicines as having something in common and as being 
holistic, natural, or spiritual, whereas in fact these healing systems vary 
greatly and are often as material and pragmatic as they are holistic or 
spiritual.
Ayurveda actually has a lot in common with Western biomedicine; 
both systems intervene in the physiology of the body through the use of 
pharmaceuticals and other therapeutic modalities. One could argue that 
Ayurveda is more holistic than Western biomedicine in the sense that it 
takes into account diet, the season, and other environmental factors more 
often than biomedicine does. But a typical ayurvedic medical consultation 
will focus on symptoms and physiology as understood in ayurvedic terms. 
The patient will describe symptoms, and the doctor— or vaidyan, as 
ayurvedic practitioners are often known— will palpate the patient’s body, 
perhaps listen with a stethoscope (since Ayurveda has adopted some tools 
of Western biomedicine), and ask the patient questions. Then the vaidyan 
will make a diagnosis, using one of the Sanskritic terms for diseases in 
Ayurveda, such as asmari or kapha unmada, and assess the effect on the 
three dosas, or bodily characteristics, vata, pitta, and kapha , and other 
factors. Sometimes the diagnoses have clear correspondences to Western 
medical diagnoses, such as asmari, which is kidney stones, and sometimes 
they are harder to translate, such as kapha unmada, which resembles de­
pression but has different characteristics.6
Though its earliest texts date back about two thousand years, Ayurveda 
is a contemporary, thriving practice. It is taught in ayurvedic medical 
schools throughout India, and it features schema for understanding health 
and illness, such as the dosas, bodily substances known as dhatus, and 
myriad other factors. These schema help practitioners understand the ef­
fects of food and environmental factors on health and illness and are the 
basis of an extensive pharmacopoeia of ayurvedic plant-based medicines 
that some fear will be copied and patented. Research journals present 
new clinical studies in Ayurveda, but the issue of whether Ayurveda offers 
new inventions or is based on past truths of medical insight is unclear 
and, as we shall see, a problem for how ayurvedic knowledge relates to 
patent law. Ayurvedic medications are produced in factories that process 
and refine raw plant materials, but ayurvedic pharmaceutical producers 
do not isolate active chemical entities as is done in Western biomedicine.
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Thus Ayurveda is arguably more “natural” than biomedicine, even though 
plant ingredients are pulverized, evaporated, cooked, and otherwise pro­
cessed by machines in factories to make ayurvedic drugs. Some ayurvedic 
doctors prefer not to prescribe factory-produced medicines and instead 
mix medicines, which they tailor to specific patients’ problems, in their 
own offices. Thus minor innovations are constantly created in the practice 
of ayurvedic medicine. Sometimes individual doctors’ formulations have 
been kept secret, but no legal ownership rights have been claimed for these 
creations— that is, until the WTO upped the ante in the world of intellec­
tual property by creating an environment that led practitioners to be more 
protective about their innovations.
India is also a major producer of pharmaceuticals of Western medicine, 
or what is referred to as “biomedicine” in this book. Medical anthropolo­
gists prefer the term “biomedicine” partly because this medical system is 
no longer, and rarely has been, exclusively “Western.” Also, there are other 
medical systems that derive from the same Western— specifically Greek—  
origins of biomedicine, such as India’s Unani medical system. In India, 
“biomedicine” is known as “English medicine,” “modern medicine,” and 
“allopathy.” The term “alternative” medicine is not used because several 
medical systems, including biomedicine, Ayurveda, and homeopathy, are 
considered mainstream, but biomedicine is the dominant system in terms 
of government and private financial and institutional support.
The Indian biomedical pharmaceutical sector is huge, and India-based 
companies, many of which operate in countries all over the world, have 
been a source of inexpensive medications for individual consumers and 
public health programs, supplying low-cost antiretrovirals for AIDS 
treatment programs in sub-Saharan Africa, which has 70 percent of the 
global burden of HIV/AIDS, and cost-saving generic drugs to US con­
sumers. While the role of Indian pharmaceutical companies in supplying 
affordable medications for the international AIDS crisis has received media 
attention, the degree of consumption of Indian pharmaceuticals in the 
United States and other high-income countries is less well known. Eighty 
percent of the active ingredients in all drugs consumed in the United States 
are produced in India and China.7 In addition to active ingredients, many 
of the final drug products are produced by Indian companies. US consum­
ers may not be aware that 40 percent of the prescription medicines they 
pick up from their pharmacies come from India, even though a company
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name such as Aurobindo, Ranbaxy, or Sun Pharmaceuticals appears on 
the label.8
Indian pharmaceutical companies, however, have had to rework their 
business practices after the World Trade Organization enacted TRIPS, and 
India had to change its Patents Act to allow product patents for medica­
tions. Now drug products can be patented in India and can only be pro­
duced with permission, usually in the form of a license from the patent 
holder, and an accompanying payment of royalties.
This seemingly slight change from process patents to product patents 
in 2005 confers exclusive market control of medications to single compa­
nies and could have major international public health effects if this causes 
prices of essential medicines to rise. Already, controversy has stirred over 
the effects of the new patent regime, with court cases mounted in opposi­
tion to new patents and applications for licenses to override patent rights 
in the name of public health submitted in India, Brazil, and other places. 
Meanwhile, some multinational drug companies have voluntarily licensed 
the right to produce some of their medications to Indian companies, keep­
ing the prices of certain treatments for HIV/AIDS relatively low for now. 
These trends need careful monitoring, since thirty-seven million people in 
the world are living with HIV, and only 46 percent of them have access to 
these lifesaving medications.9
Practitioners of Ayurveda have been concerned by the new patent 
regime but uncertain about how it would affect them, since Ayurveda 
relates ambiguously to the provisions of patent law. Patents protect inno­
vations that are useful, novel, and non-obvious and that are individually 
created rather than the product of collective, shared knowledge. Innovation 
in Ayurveda is both individual and collective, novel yet always in dialogue 
with classic principles. It is based on knowledge about the physiological 
effects of plants but does not involve isolating active ingredients, which 
would make their therapies patentable since one cannot patent plants 
(unless they have been genetically modified). In some ways, biopiracy does 
not seem to threaten the practice of Ayurveda directly, since biomedical 
products, which use chemically isolated ingredients rather than plant ma­
terials, would not be used by ayurvedic practitioners, and ayurvedic phar­
maceutical producers should be able to continue to use medicinal plant 
materials even if active chemical ingredients extracted from them were 
patented by others. But this patent system seems unjust to Ayurveda’s
Introduction
defenders, since it protects rights for biomedical products but does not 
defend ayurvedic innovation in the same way— confirming that science 
and the law, like any other social practices, are culturally inflected.10 For 
example, reserpine, the antipsychotic drug developed from ayurvedic 
insights, which is now used as an antihypertensive, continues to make 
over $200 million a year in sales for the biomedical drug companies that 
produce it, but no ayurvedic practitioners have seen a share of these prof­
its ." In response, ayurvedic activists are digitizing ayurvedic knowledge 
through the TKDL as a resource to use in opposing patents while some 
ayurvedic practitioners are developing products that they think are pat­
entable, possibly changing the practice of Ayurveda in the process.
In exploring controversies over the ownership and control of medical 
knowledge in a post-WTO world, this book highlights the vicissitudes and 
dangers of this new environment while revealing moments of opportunity 
for a more equitable future in this regime of ownership that may affect 
access to medicine for a large portion of the world’s population. To do 
so, the book takes into account actors that have much at stake in the new 
patent environment, including activists concerned with the price of essen­
tial medicines, United States- and India-based pharmaceutical companies, 
and ayurvedic practitioners and producers.
Overextending Intellectual Property
The idea of intellectual property and its application in the new patent re­
gime are not wholly nefarious, oppressive, and without productive conse­
quences. Like the legal scholar and critic of the current IP regime, James 
Boyle (2008), I do not object to intellectual property in principle. The idea 
of giving an innovator a temporary monopoly over an innovation condi­
tional on the public disclosure of how the innovation works balances indi­
vidual and public interests and was an improvement on an earlier system 
where innovators simply kept the formulations behind their creations se­
cret. This secret often died with the innovator rather than becoming part 
of the public domain as innovations now do after twenty years under pat­
ent law. What is problematic is the overextension of intellectual property 
law and the use of obfuscating myths of individual invention that justify 
it. Scholars have examined myths that support principles of intellectual
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property showing that claims of individual invention obscure the collec­
tive and incremental nature of innovation in medicine, science, and the 
arts.12 Patents, for example, protect the collective invention of employees 
of a corporation only because a corporation is legally, though not actually, 
an individual, while the collective knowledge of a community or an indig­
enous medical system is not patentable.
Before the W TO, when nations crafted their intellectual property laws 
with greater autonomy, people around the world were freer to borrow, 
share, or appropriate each others’ knowledge and creations. Today, be­
cause patent cordons are being reinforced mostly at the behest of powerful 
commercial interests, less privileged forms of knowledge are also being 
cordoned off, leading to a loss of creativity, a reluctance to share knowl­
edge, and a shrinking of the public domain. This reinforces observations 
by critics who lament the loss of an intellectual commons that comes from 
both sides of intellectual property struggles, the powerful interests that 
advocate for expansive IP law and the groups that resist these expansions 
by establishing defensive claims.13
In Indonesia, the government’s defenses of indigenous knowledge and 
arts— from contemporary theater to textiles to classical dance— through 
new intellectual property laws limit the borrowing of ideas from Indo­
nesian cultures by outside artists. This restricts the possibility of cultural 
exchange and works against the interests of the artists the Indonesian 
government claims to be defending, who want their products to be used 
and circulated by outsiders.14 Likewise, people in India and the Indian 
state often celebrate how their cultures, medicines, and sciences have been 
adopted around the world— from yoga to Gandhian nonviolence to the 
concept of zero in mathematics and even ayurvedic medicine— but such 
contributions to global patrimony, and even the discovery of new treat­
ments for diseases, may be threatened by the Traditional Knowledge Digi­
tal Library and other attempts to encode and protect knowledge systems.
Even before the rise of modern globalization, cultural hybridity was 
commonplace, and the adoption and sharing of different cultural and 
scientific ideas— borrowing that today might be considered forms of 
piracy—was the norm. We take for granted that, until recently, we had been 
living in a world where an open public domain was maintained, often 
simply because there were fewer laws limiting the circulation of innova­
tions. Europeans did not have to pay royalties to China every time they
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made pasta, brewed tea, or set off fireworks because of the Chinese ori­
gins of these innovations. Mathematicians and engineers did not have to 
figure out which numerical concepts came from Indian, Greek, or Arab 
sources and get the necessary permissions to continue their work.15 While 
restrictions on the sharing of knowledge and innovation, whether artistic 
or scientific, represent a loss to human creativity and scientific discovery, 
researchers who examine recent IP controversies argue that we need to be 
wary of the ideal of an open public domain, which, like many rational- 
actor or level-playing-field ideals, ignores social inequalities that give 
more powerful interests a greater ability to extract and benefit from com­
munal resources.16 It is also not appropriate to suggest that both sides—  
the corporate interests and the defenders of local knowledge— share equal 
blame for the current partitioning of the world’s knowledge. The defenses 
of Ayurveda, yoga, and the arts in India, Indonesia, and elsewhere are 
best seen as a reaction to the corporate actors who initiated this standoff.
Reacting to Globalization: Power, Complexity, 
and Vulnerability
In analyzing the struggles between activist, corporate, and government 
actors, this book provides an example of how people react to and resist 
forces of globalization. Global initiatives and agreements constantly re­
shape the socioeconomic world we live in today, and understanding and 
reacting to these forces— or what I call “constellations” of power to refer 
to their multilayered nature and their complexity— can be daunting. W TO 
mandates, such as TRIPS, free trade agreements, such as NAFTA and the 
proposed Trans-Pacific Partnership (which contains new IP protections), 
and the constant movement of industrial production in pursuit of low-cost 
labor regularly remake our world, but it can be difficult to discern what 
will be their effects.
Thus, this examination of the current struggle over intellectual prop­
erty claims considers the legibility of power, which refers to how difficult 
it is to understand a system of power, such as the new patent regime, for 
people whose lives it affects and even for the journalists, researchers, and 
activists who assess such systems and decide what to do about them. For 
a long time, analyses of power and resistance considered power relations
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that were relatively easy to read or where the threat, and who was behind 
it, was clearer. For example, labor exploitation of peasants and indigenous 
people and the seizure of land by Hispanic elites led to the Mexican Revo­
lution and similar uprisings in the twentieth century.17 The threat of fascist 
and authoritarian leaders like Mussolini and Suharto was also relatively 
easy to perceive.18 The political scientist James Scott famously argued that 
often resistance does not result in open revolt but takes place through 
what he called “everyday forms of resistance” such as foot dragging, work 
slowdowns, pilfering, and other methods, but the conditions people were 
reacting to were relatively clear to those who were affected: landlords 
were raising the rent, mechanization was putting people out of work.19
Today, amorphous “forces of globalization” are harder to decipher. 
They are mysterious, daunting, and difficult to figure out how to resist. 
These networks of power are also like rhizomes, to use a popular meta­
phor proposed by social scientists and philosophers for analyzing science, 
technology, and social networks.20 A tree is hierarchical and centralized, 
with a trunk from which branches break off and divide into smaller 
branches, ending up at the smallest level like capillaries in the human 
body, and all dependent on the center. The rhizome, on the other hand, 
is a mostly subterranean structure of roots that goes out in every direc­
tion, constantly forming new junctions and networks from which plant 
shoots pop up at various intervals. Unlike the tree, there is no center in 
the rhizome. The structure continuously reproduces itself as it moves out 
through space in multiple directions. There is no trunk, stem, or root 
structure that, if severed, affects the whole organism. If one were to cut 
the roots of the rhizome, it would continue to send out new branches and 
shoots in different directions as long as there were space and nutrients. 
The new global intellectual property regime is in some ways like the tree, 
since the W TO was central in its implementation, but it has taken on the 
structure of a rhizome, sending shoots up in different countries as laws are 
changed and new supporters or adherents are added to the network. Some 
supporters at new nodes in the network appear at first to be resistors, as 
in the case of those in India who are working to protect Ayurveda through 
the TKDL. Although this effort is aimed at protecting knowledge from 
misappropriation, it at the same time affirms the principles of intellectual 
property of the new regime by preparing to mount oppositions to patents 
using provisions of patent law— specifically by proving that biomedical
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pharmaceuticals derived from Ayurveda are based on prior knowledge 
and therefore not patentable. This amounts to an agreement to the prin­
ciples of patent law that are central to the new IP regime.
In trying to understand what she calls “the state of globalization” 
today, the social anthropologist Shalini Randeria speaks of the unwieldy 
and complex nature of contemporary forces that involve webs of corpo­
rate and government actors and multiple legal regimes.21 In earlier stud­
ies of power and resistance mentioned above, people objected to policies 
of their landlords, bosses, or government leaders. Today, the government 
and local officials are as likely to be allies as adversaries, since the “law 
today transcends state boundaries in complex and significant ways due to 
a proliferation of actors, arenas, methods and forms of rulemaking and 
dispute resolution located at different sites around the world.”22 Randeria 
considers the multiple legal regimes that India must negotiate, including 
TRIPS and the Convention on Biological Diversity, and concludes that “in 
the new architecture of global governance, power is diffuse and elusive.”23
Francis Gurry of the United Nations World Intellectual Property Orga­
nization (WIPO) similarly points to the growing complexity that interna­
tional policies and agreements have taken on in the wake of TRIPS, where 
organizations, such as the Convention on Biological Diversity, the Food 
and Agriculture Organization, and UNESCO, have suddenly had to work 
intellectual property positions into their agendas, when they did not have 
to do this in the past. The dynamics of power and resistance have been 
a major focus of social science research for several decades now, but this 
diffuse character of power— which renders it illegible and makes strategies 
of resistance difficult to devise— has not been central to that research.24
Thus global constellations of power, like the new intellectual property 
regime, are multilayered and constantly changing, and attempts to resist 
them can lead to unanticipated results. A rhizomatic structure is difficult 
to dismantle or resist. In the case of the effect of the new IP regime on 
ayurvedic medicine, the threat is hard to decipher, and ayurvedic practi­
tioners and activists have engaged in a variety of reactions, which include 
deliberate inaction, hoping that by “lying low” and not engaging with 
the new regime there will be no threat. Defenders of Ayurveda must deal 
with an extra layer of complexity, since they are trying to understand how 
their system of medicine relates to patent law and whether and how their 
knowledge needs to be defended, but few people have the legal, political,
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and ayurvedic expertise to assess these issues. For biomedical pharmaceu­
tical production, there is a little more clarity.
If one severs the roots of a rhizome, there will be little effect on the 
plant network. Similarly, creatures of mythology, such as the hydra or the 
cyclops, seemed daunting, but they always had some vulnerability that 
the hero could find to subdue the creature. This is somewhat like what activ­
ist groups and government representatives in India have managed to do 
through legal maneuvering within the new patent regime, notably by add­
ing an obscure-sounding provision to the country’s new patent law, Section 
3d. While they have not actually “subdued” the new regime, we might say 
these efforts have “domesticated” it by limiting its negative effects in India 
and for places that depend on India’s low-cost drug supply. This story of 
heroism is not well known, most likely because it involves legal techni­
calities that seem complicated and obscure, but basically, small activist 
groups in India, such as an organization of HIV-positive people assisted by 
a handful of activist lawyers, have been able to defeat patent applications 
by multinational companies in the India Patent Office, and their efforts are 
aided by Section 3d’s rigorous standard for patents to be awarded in India.
Section 3d creates a more balanced patent law that resembles the origi­
nal principle of intellectual property as a temporary and limited social 
contract that protects real innovation, rather than what IP has become 
today, a tool for expanding the reach of private property. The oppositions 
based on Section 3d prevent what some have seen as frivolous patents 
that have been awarded in other places, such as the United States, for 
me-too drugs. Section 3d requires that new versions of drugs show greater 
effectiveness than the older versions to obtain a patent. While this does 
not sound like an unreasonable requirement, it has brought the ire of the 
pharmaceutical industry. This provision prevents Indian patents of several 
medications that were profitable for pharmaceutical companies elsewhere, 
and it was added, at the behest of leftist parties, to India’s new intellec­
tual property laws. Corporations got what they wanted in the W TO with 
TRIPS, but they did not anticipate India adding this section that would 
limit its effects. Needless to say, “big pharma” did not see the creation of 
Section 3d as heroic, but rather as an unfair restriction on their property 
rights. Swiss-based multinational giant Novartis challenged Section 3d in 
India’s Supreme Court, but in a decision handed down in 2013, the court 
ruled this provision was legal and allowable under TRIPS.
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The metaphor offered earlier of trying to defeat a mythical beast is 
appropriate because it calls attention to the fact that global constellations 
of power such as the new patent regime are complex and intimidating. 
The metaphor’s weakness is that it depicts a uniformly dangerous and 
malign threat whereas the new patent regime is not so simple, and, unlike 
a mythical beast, it has its allies. Enthusiasts of the “free market” model 
believe that increasing corporate profitability through strict property con­
trols will float all boats and spur economic growth in many sectors, and 
strong IP protections will create incentives for corporate innovation in all 
W TO member states. There are many problems with such “free market” 
ideals— and one of them is that TRIPS is more about WTO and govern­
ment intervention in favor of corporate interests than freeing markets—  
yet the new patent environment is not wholly nefarious, and it has led to 
unexpected opportunities that have some benefits, such as development 
of new products by Indian pharmaceutical companies. These products do 
not merely add more drugs to the overly medicated privileged strata of 
society in India and high-income countries; they also show promise in ad­
dressing neglected diseases of low-income areas that large, multinational 
pharmaceutical companies ignore.
Finally, this book takes pharmaceutical companies seriously as impor­
tant, and unavoidable, actors with legitimate concerns. Without a doubt 
these corporations have an unfair share of power to conform economic 
policy to their interests, but we will see how the caricature of an all- 
powerful “big pharma,” often found in social science and public health 
research, ignores the complexities and varied agendas of pharmaceutical 
producers.
Studying Pharmaceutical Producers
This book builds on other work that has explored the expansion of in­
tellectual property rights in the last few decades.25 Most of those stud­
ies focus on Europe or North America and explore these issues from legal 
and textual sources. Less attention has been paid to the most significant 
sites of current patent struggles, such as India, one of the world’s largest 
pharmaceutical producers with a history of sharing medical knowledge 
with the West, and we have not learned much about how actual people
Introduction 15
in pharmaceutical production respond to the new legal regime.26 I chose 
to follow these issues over an extended period of time, tracking the ma­
neuvers of the W TO, pharmaceutical corporations, and Indian govern­
ment protections of indigenous medical knowledge in the media from the 
period before 2005, when India implemented the new intellectual prop­
erty rules, and for several years after. Like other work on the new patent 
regime, this book depends on documentary and legal sources, but I sup­
plemented these observations with insights from pharmaceutical produc­
ers involved in the struggles and opportunities created by the new patent 
environment by speaking with individuals involved in the protection of 
ayurvedic knowledge and employees of ayurvedic and biomedical phar­
maceutical companies in India and the United States.
The issues considered in this book are constantly emerging and evolv­
ing, making it challenging to offer definitive pronouncements on them. As 
I was including genes in the list of objects that are now subject to IP claims 
in this introduction, the United States Supreme Court ruled that naturally 
occurring, unaltered genes could not be patented, striking down Myriad 
Genetics’ claim to own the BRCA breast cancer genes but affirming that 
synthetic genes could be patented.27 Meanwhile, legal precedents continue 
to emerge from India, such as the 2013 Indian Supreme Court decision 
upholding Section 3d of the 2005 Patents Act. While the terrain is always 
shifting, it is valuable to try to make an accounting of where we are and 
where we are heading.
My own assessment of the effects of the patent regime has changed 
over the course of my research on this issue. In an earlier analysis of the 
emerging patent environment, I raised the concern that the new regime 
will have a dire impact on global public health because it will most likely 
raise the price of medications that have been developed since the new 
regime came into effect, such as treatments for new forms of HIV/AIDS 
that are becoming resistant to the first line of antiretroviral drugs (ARVs). 
This could have a devastating effect on ARV programs in low-income 
countries.28 Yet in the case of tenofovir, one of the most important first- 
and second-line AIDS treatments that has come out under the new patent 
regime, the price in low-income countries has come down dramatically, 
from $200 per person per year to $26 per person per year, because of vol­
untary licensing agreements that the patent owner, Gilead Sciences, issued 
to multiple Indian generic pharmaceutical manufacturers, allowing them
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to produce the medications. Thus one of the earliest and most well docu­
mented examples of pricing under the new patent regime was not what I, 
and others, anticipated. This raises the possibility that the effects of the 
new patent laws may not be as dramatic as expected. As we will see later, 
such voluntary licensing practices have their limitations, and we will have 
to monitor whether the tenofovir scenario is repeated with other essential 
medicines as drug production under the new regime continues.
Also, some were concerned that the new patent environment would re­
sult in Indian pharmaceutical companies being acquired by multinational 
producers and becoming a source of cheap scientific labor for making 
medications. This has not happened— or not happened yet—and this con­
cern assumes a simplistic opposition between multinational “big pharma” 
and a vulnerable Indian generic sector. Many India-based companies are 
large and multinational. Meanwhile, some foreign-based companies are 
generic producers, and some India-based companies have developed and 
marketed their own branded products. The first pharmaceutical devel­
oped and patented under India’s new law by an India-based company is 
Ranbaxy’s Synriam (arterolane maleate and piperaquine phosphate),29 an 
antimalarial that will help treat a disease that has been neglected by other 
multinational companies.
Despite my training in anthropology, this book is not heavily ethno­
graphic, although it uses ethnographic methods and presents ethnographic 
perspectives not typically offered in other assessments of the new intellec­
tual property regime. I based some of my claims on following institutions, 
the implementation of laws, and efforts by activists over the last twelve 
years through information I gathered from the media and other public 
records such as press releases and documents available on interest-group 
websites. The analysis of the emergence of a new legal regime and its 
impacts on public health, practitioners, and corporations does not easily 
lend itself to the fly-on-the-wall orientation of participant observation, 
the signature method of anthropology, which in this case would ideally in­
volve observing people in the workplace. Still, I gained important insights 
from doing field research. Discussions with ayurvedic practitioners and 
producers who were not directly working on projects such as the TKDL 
but who were concerned about patent issues were the easiest to initiate 
and provide an important perspective. Fieldwork around ayurvedic prac­
titioners working on the TKDL or inside pharmaceutical companies was
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not as feasible, although it was attempted with limited success. I did also 
manage to meet with, and interview, other important stakeholders and 
activists in India and the United States. This blend of methods is an effec­
tive way— but not the only way— to study the emergence of a new legal 
regime. It enabled me to take account of slowly evolving processes along 
with the views of local actors, and it is appropriate when one is “studying 
up” powerful institutions as I did in examining pharmaceutical company 
policies and practices.
In the 1970s, the anthropologist Laura Nader urged researchers to 
“study up,” which refers to doing ethnographic work on powerful in­
stitutions, not just marginalized people, everyday practices, or exotic 
others.30 Efforts to study up have become increasingly popular, but as 
Hugh Gusterson points out, based on his ethnographic studies of nuclear 
weapons scientists, people in powerful institutions or elite positions usu­
ally do not welcome scrutiny and they often have the means to avoid 
it. This difficulty in studying up Gusterson labeled the “Roger and Me 
syndrome,” a reference to the Michael Moore documentary where Moore 
tries to interview the CEO of General Motors, only to be turned away re­
peatedly by security personnel. Gusterson thus advocated “polymorphous 
engagement” with powerful subjects, which involves a variety of methods, 
including interviewing where possible, conducting ethnographic observa­
tions in peripheral spaces, such as workplace cafeterias and waiting areas, 
and doing research based on news and other textual sources.31
The research in India was conducted during brief fieldwork in Kerala 
in 2004 and 2005 that focused on meetings with ayurvedic practitioners 
and producers and legal and public health experts. In a subsequent visit 
in 2012, I conducted interviews with ayurvedic practitioners, legal ana­
lysts, and pharmaceutical company representatives in Hyderabad, Delhi, 
and Kerala. Hyderabad, a historical, multicultural city that was once the 
center of a large kingdom ruled by a succession of Nizams, is now the 
pharmaceutical hub and a high-tech boomtown of southern India. Delhi is 
one of the nation’s megacities, home to several pharmaceutical companies 
as well as government workers who analyze national policy, including 
intellectual property provisions. Kerala is a state in southern India where I 
have conducted ethnographic research on a range of issues related to med­
ical anthropology and public health. The state is, in essence, the ayurvedic 
pharmaceutical hub of India, the lesser-known counterpart to Hyderabad,
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and Kerala is renowned for its concentration of ayurvedic physicians and 
institutions, including clinics, hospitals, and even psychiatric facilities. 
Many have come to Kerala seeking the region’s local knowledge about 
medicinal plants, starting with Hendrik Adriaan van Rheede, a Dutch 
official stationed in Cochin, who, in the seventeenth century, compiled 
the famous Hortus Malabaricus, an encyclopedia of botanical knowledge 
from this part of India that aided the development of biological science 
in Europe.
Observations about ayurvedic medical practices are based on these 
visits as well as fieldwork conducted since the early 1990s on ayurvedic 
treatments for psychopathology, and I continued to monitor develop­
ments related to the new IP regime in the Indian media during an eight- 
month stay in India in 2013-2014  that was focused on a different research 
topic.32
The process of trying to speak to representatives of pharmaceutical 
companies that were key players in the new patent regime was fraught 
with challenges characteristic of the “Roger and M e” syndrome. I believe 
that pharmaceutical companies in the United States and India want to 
avoid direct interaction with researchers. They prefer to control what is 
said to the public through press releases and presentations on their web­
sites, but those pharmaceutical employees I was able to speak with were 
forthcoming and helpful in discussing how they respond to the new patent 
environment, although they were, no doubt, a self-selected group. Thus 
in addition to analyzing pharmaceutical company perspectives on pat­
ent controversies and presenting an encouraging example of price reduc­
tions through partnerships between United States-based Gilead Sciences 
and several India-based companies, I will examine corporate obfuscation 
showing how companies’ preference for one-way communication contrib­
utes to the difficulty in deciphering systems of power today.
The History of Intellectual Property and 
the Current Regime
The next two chapters examine the development of intellectual property 
law in Europe and the recent expansion of this type of property rela­
tion around the world while also highlighting features of India’s changing
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patent laws and activists’ attempts to use these laws to oppose patents. 
The book then moves on to examine the perspective of pharmaceutical 
producers, showing how ayurvedic practitioners and producers, United 
States-based pharmaceutical companies, and Indian pharmaceutical com­
panies navigate the new terrain of intellectual property.
Chapter 1 sketches the history of the concept of intellectual prop­
erty from its emergence in fifteenth-century Europe through its expan­
sion in the late twentieth century with the World Trade Organization 
TRIPS agreement. Chapter 2 considers the public health effects of the 
change from a process to a product patent regime in India, the primary 
supplier of essential medicines for low-income countries, and examines 
how activists in India, such as the Lawyers Collective and the Indian 
Network for People Living with HIV/AIDS, have defeated recent patent 
applications.
Chapter 3 highlights the history of the sharing of medical knowl­
edge between India and the West and analyzes the divergent reactions 
of practitioners and producers of ayurvedic medicine to the new patent 
regime, some of whom oppose the regime and some of whom try to cre­
ate proprietary ayurvedic medicines. Chapter 4 presents the perspective 
of multinational pharmaceutical companies, with a special focus on Gil­
ead’s voluntary licensing program that has allowed Indian companies to 
make several of Gilead’s antiretroviral products, bringing down the price 
of important medicines for AIDS in low-income countries. We will learn 
that for these companies, the main priority under the new patent regime 
is to protect their markets in wealthy and middle-income countries, and 
the main problem of drug access may turn out to be for the poor who live 
in middle-income countries such as Brazil and China. Chapter 5 critiques 
the distinction between “multinational” pharmaceutical companies, or 
“big pharma,” and “Indian” pharmaceutical companies used in many 
analyses, and presents discussions with representatives from two Indian 
pharmaceutical companies, which address patent licenses, economies 
of scale— the special capacity of the Indian pharmaceutical sector— and 
prospects for research and development in India, which has recently pro­
duced new drugs for cancer and malaria.
Before further examining the role of these actors involved in pharma­
ceutical creation and production, it will be necessary to understand where 
the concept of intellectual property came from. Intellectual property does
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not really exist until innovators create this concept starting in fifteenth- 
century Venice. This is a particular European view about property re­
lations built largely on romantic ideals of individual innovation, and it 
is remarkable that these culturally specific ideas about ownership have 
spread to the point where most of the globe is conforming to a single intel­
lectual property regime.
1The Invention and Expansion of 
Intellectual Property
In a compelling study of our shrinking creative and cultural commons, 
The Public Domain (2008), the legal scholar James Boyle alerts us:
We are in the middle of a second enclosure movement. While it sounds gran­
diloquent to call it “the enclosure of the intangible commons of the mind,” 
in a very real sense that’s just what it is. . . . Once again things that were 
formerly thought of as common property, or as “uncommodifiable,” or out­
side the market altogether, are being covered with new, or newly extended, 
property rights. (45)
The first enclosure movement, which developed over the course of the fif­
teenth to nineteenth centuries in England, involved the privatization of 
what were once common lands, while this second enclosure movement 
involves the privatization of creative and intellectual realms through in­
tellectual property laws. Despite sounding the alarm about the new enclo­
sure movement, Boyle’s book opens with a defense of the basic principles 
of intellectual property law.
2 2 Chapter One
In the case of patent law, Boyle explains that this kind of protection 
is preferable to the previous method of gaining a commercial advantage 
through the maintenance of secrecy that was used, for example, by me­
dieval guilds. The problem with secrecy is that the invention does not 
get broadly produced so that the greater society can enjoy its benefits, 
and its usefulness to society may die with the death of the innovator. 
Some ayurvedic doctors use this method of keeping their formulas to 
themselves to control the use of their innovations. Most ayurvedic prac­
titioners I spoke to were not, however, enthusiastic about this method. 
They explained that they preferred that knowledge be shared, and they 
complained that formulations that were kept secret died with their “own­
ers.” A patent, which is a time-limited contract between the innovator 
and society, and not a guarantee of enduring ownership, ensures that 
innovations remain as public resources after the expiration of a patent 
and after the death of an inventor. Boyle explains that through this con­
tract, society is assuring innovators that if they publically disclose their 
invention— in enough detail so that others will be able to recreate it—  
the state will give them a temporary monopoly to produce the invention 
or transfer the rights to benefit from its production. After the term of 
the patent expires, the invention will become part of the public domain, 
available for anyone to produce. Should the inventor not wish to divulge 
how the invention works after the expiration of the patent or if the inven­
tor dies, society will have an explanation of how the invention works “on 
file,” even though the form of the record of the patented invention has 
changed over time.1
Boyle goes on to explain the other key forms of intellectual property, 
copyrights and trademarks that protect artistic works and symbols of 
trade, and then asks:
But does intellectual property work this way now, promoting the ideal of 
progress, a transparent marketplace, easy and cheap access to information, 
decentralized and iconoclastic cultural production, self-correcting innova­
tion policy? Often it does, but distressingly often it does the reverse. The 
rights that were supposed to be limited in time and scope to the minimum 
monopoly necessary to ensure production become instead a kind of perpet­
ual corporate welfare— restraining the next generation of creators instead of 
encouraging them. (8-9)
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Boyle adds that through extensions of the life of copyrights to, in many 
cases, over a century, at least in the United States, “most of twentieth 
century culture is under copyright— copyrighted but unavailable. Much 
of this, in other words, is lost culture” (9). This is because books, films, 
and music are often not made available to the public because of fear of 
infringement.
Although the life of a copyright has been extended to over a hundred 
years, in most cases the life of a patent remains at twenty years. It is the 
enforcement of patents that has been extended, along with the applica­
tion of United States-style patent law through the W TO, which includes 
product patents for medications and overrides much local variability in 
patent provisions. A key rationale of patent law, the assurance that after 
investing in research and bringing a new drug to market others cannot 
come along immediately and copy it, is now used as “a kind of black­
mail” where “industry leaders and lobbyists routinely warn that lower 
prices will reduce funds for R& D  and result in suffering and death that 
future medicines could reduce.”2 Such appeals to the importance of re­
covering investments, however, obscure the significant amount of public 
money that goes into innovations for which corporations claim exclusive 
rights. Nonetheless, pharmaceutical companies have effectively mobilized 
the ideology of intellectual property and the threat of diminishing future 
drug development to advocate for the expansion of their property claims.
The Invention of Intangible Property
Anthropologists have tried to determine whether intellectual property or 
similar protection for intangible forms of property exists outside of Euro­
pean societies or before capitalism and its sanctification of private property 
became the global norm. Their findings have, however, been ambiguous. 
In 1928, Robert Lowie claimed something like intellectual property, or 
“incorporeal property,” to use his term, existed in precapitalist societies 
in the form of rights to songs and secrecy of certain kinds of knowledge. 
He cites, for example, research on the Eskimo, among whom “a commu­
nistic trend as to economic necessaries is coupled with strict individualism 
as to the magical means of securing food,” and describes the process by 
which ritual knowledge and songs may be “purchased” among Blackfoot
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Native Americans.3 A. Irving Hallowell retorted that this indicates some­
thing like mere possession, which is not equivalent to formal property 
rights, since such claims do not have the “commercial flavor” seen in con­
temporary property claims.4 Countering those who argue that non-Western 
peoples do not have principles that resemble intellectual property and 
believe only in communal ownership, Michael Brown offers examples of 
Kiowa and other Native American practices of individual ownership of 
songs, designs, and other forms of intangible property. He adds that “the 
rules controlling the flow of ideas and information are often hard to rec­
oncile with Western practices and, perhaps more significantly, with the 
replicative technologies spawned by the Industrial Revolution.”5
It is difficult to determine whether practices such as secrecy about 
knowledge and “owning” songs constitute predecessors to what we know 
as intellectual property. If Michael Brown is right, it may be the “rep­
licative technologies,” such as mass printing and mass manufacturing, 
that spur the creation of actual legal protections for intellectual property. 
Doctors of ayurvedic medicine speak about the maintenance of secrecy of 
some doctors’ formulations as if it is similar to intellectual property law. 
This practice may predate the commodification of medical products that 
developed with colonialism and capitalism, or it may be a more recent 
response to commodification, a defense against the practice of making and 
selling medical products for a profit.
The emergence of modern intellectual property law can be more dis­
tinctly defined. The granting of patents as privileges to market inventions—  
but not as ownership of the concept behind the invention— dates back 
to fifteenth-century Venice. The elements of modern patent law— which 
protects the information that is the basis of an invention— can be traced to 
transformations in claims of ownership and ideas about mental and physi­
cal labor in eighteenth-century Europe and the United States.6
The science historian Mario Biagioli highlights a shift that occurred 
around 1790, when the state stopped conceiving of patents as privileges 
and began protecting patents as rights. New specification requirements for 
patents replaced the principle that the invention was a material thing the 
inventor presented before representatives of the state to claim ownership. 
Patent laws adopted in France and the United States in the late 1700s 
required a precise description of the invention on paper and resulted in 
the protection of the idea behind the invention as property: “Allowing for
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the emergence of the idea as a distinct entity, specifications made possible 
for that idea to become the immaterial ‘essence’ of the invention.”7 This 
is the basis of the social contract behind patent law that we have today, 
where the state gives the innovator a temporary monopoly on his innova­
tion in exchange for the innovator’s public disclosure of the invention in 
enough detail so that others can reproduce it after the patent expires or 
the inventor dies.
Similar principles emerged in the development of copyright law after the 
passage of the Statute of Anne in England in 1710. The statute claimed that 
“printers, booksellers, and other persons have of late frequently taken the 
liberty of printing, reprinting, and publishing, or causing to be printed, re­
printed, and published, books and other writings, without the consent of 
the authors or proprietors of such books and writings, to their very great 
detriment, and too often to the ruin of them and their families.” “For 
the encouragement of learned men to compose and write useful books,” 
it awarded exclusive rights to print books to their authors and to those 
booksellers and printers to whom the authors assigned their rights.8 Thus 
the book trade’s “claims of proprietorship extended not only to the par­
ticular books they published, but to the content of those books.”9
Starting in the late 1700s, Wordsworth and other Romantic authors 
promoted the ideas that creative works came from an individual well- 
spring of creativity and that writers could be said to own these works. 
Before then:
Writers, like other artisans, considered their task to lie in the reworking 
of traditional materials according to principles and techniques preserved 
and handed down to them in rhetoric and poetics— the collective wisdom 
of their craft. In the event that they chanced to go beyond the state of the 
art, their innovation was ascribed to God, or later to Providence. Similarly, 
in the sphere of science, invention and discovery were viewed as essentially 
incremental— the inevitable outcome of a (collective) effort.10
References to the romantic myth of the individual inventor in this book 
thus invoke two meanings of “romantic”: it is “romantic” in the sense 
that it is an ideal and not a reflection of the actual practice of innovation, 
and it is “Romantic” in that it evokes a literary movement that inspired 
the idea of individual creativity in literature which is, in turn, linked to the 
notion of individual creativity in science.11
